Multi-Omics Profiling of moderate-to-severe Atopic Dermatitis and its response to systemic therapy: ‘Phenomics’ approach towards Precision medicine-based Treatment

Atopic dermatitis (AD) is a very common (prevalence 5-30% in Qatar, dependent on age group) chronic inflammatory skin diseases associated with substantial impairment of patient’s quality-of-life and considerable socioeconomic costs. Prurigo is a very debilitating disease which in appr. 50% has an atopic diathesis (AD-PN). Despite some progress in understanding and treating AD/AD-PN, there is still a gap of knowledge using molecular and immune-profiling to use precision medicine-based approaches to sustainably control moderate-to-severe AD long-term in all patients. Our objective is to test the hypothesis that the phenotypic and endotypic differences among Qatari AD patients are a result of heterogeneous molecular pathways, demanding different therapeutic approaches. T To achieve this, we will perform global and Olink proteomics as well as metabolomics/lipidomics of moderate-to-severe Qatari AD and AD-PN patients. Furthermore, we will use a 44-color FACS panel to characterize involved immune cell populations in peripheral blood of Qatari AD and AD-PN patients. Finally, we will associate the identified/short-listed candidate genes from WP1 with -omics signature and immune cell populations in patients with moderate-to-severe AD and AD-PN.

Hamad Medical Corporation